NICE Single Technology Appraisal Guidance No 193 – Rituximab
for the treatment of relapsed or refractory chronic lymphocytic
leukaemia
This NICE Guidance was
published 28 July 2010. The web reference for the appraisal and
other related documents is: http://guidance.nice.org.uk/TA193
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the
SMC advice.
The Scottish Medicines Consortium (SMC)
published a Statement of Advice (591/09) on this medication for
this indication in January 2010. This stated that:
Rituximab
(MabTheraÒ) is accepted for restricted
use within NHS Scotland.
Access the advice of the Scottish Medicines
Consortium: http://www.scottishmedicines.org.uk/smc/7157.html
3. There is no material difference between the
recommendations of the NICE STA and the SMC.
Published Date: 28 July 2010
